Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Nordic Science Capital is a biotech incubation organization based in Solna, Sweden. Founded to support inception-stage ideas emerging from leading Swedish universities, it focuses on investing in scientists who hold patents. The organization collaborates closely with these scientists in the formation of companies, patent filings, and executive roles, ensuring that innovative ideas are transformed into viable businesses.
Currently, Nordic Science Capital operates with a small team, emphasizing a hands-on approach to company formation and development. The firm has a portfolio of three companies, all in the biotech sector, and is dedicated to nurturing early-stage innovations. The organization primarily targets the European market, particularly Sweden, where it leverages its connections with local universities and research institutions.
Nordic Science Capital's unique model allows it to fill a gap in the Nordic investment landscape by focusing on inception-stage opportunities that are often overlooked by traditional seed venture capitalists. This approach has positioned the firm as a key player in the early-stage biotech investment space.
Nordic Science Capital specializes in the life sciences sector, particularly targeting inception-stage biotech ideas. The organization emphasizes a hands-on approach, working directly with scientists and researchers to develop their innovations into successful companies. The firm invests primarily in pre-seed and seed stages, focusing on companies that are in the early phases of development.
The investment strategy is centered around scientists who hold patents, allowing Nordic Science Capital to collaborate closely in the formation of companies and patent filings. This model not only accelerates the development of innovative biotech solutions but also ensures that the scientific integrity of the projects is maintained. The firm’s geographic focus is primarily on Europe, with a strong emphasis on Sweden, where it partners with leading universities to identify promising biotech innovations.
Nordic Science Capital's portfolio consists of three notable companies, each operating in the biotech sector:
These companies exemplify Nordic Science Capital's commitment to supporting innovative biotech solutions that address critical healthcare challenges. Each portfolio company is at the inception stage, highlighting the firm's focus on early-stage investments.
Dr. Lech Ignatowicz - Founding Partner. Holds a Ph.D. in Immunology from the Karolinska Institute and has co-founded five biotech companies. He has worked with Johan Paleovrachas since 2017.
Johan Paleovrachas - Founding Partner. He has led over 20 companies to a combined total of more than $100 million in sales and has co-founded three biotech firms with Lech Ignatowicz.
Vincent Weir - Partner & Chairman. A McKinsey-trained executive, he has co-founded two biotech companies and three profitable businesses in Stockholm.
Dr. Nadir Bilici - Scientific Advisor. Brings extensive expertise in the biotech field, contributing to the firm’s scientific evaluations.
Dr. Adlai Pappy - Scientific Advisor. Offers insights into the scientific and technical aspects of portfolio companies.
Stefan Lindeberg - Board Member. Provides governance and strategic oversight for the firm’s operations.
Dr. Eli Cornblath - Scientific Advisor. Contributes to the firm’s scientific due diligence and portfolio support.
Per Björklund - Advisor. Offers strategic advice based on his extensive industry experience.
Maria Rankka - Advisor. Provides insights into market trends and business development strategies.
To pitch Nordic Science Capital, founders should visit their website at ns.capital. It is recommended to include a comprehensive deck that outlines the scientific innovation, patent status, market potential, and the founding team’s qualifications. The firm prefers detailed information that demonstrates the viability of the business model and the technology.
Response times may vary, but founders should expect a thorough review process given the firm’s hands-on approach. Warm introductions are beneficial, especially from academic institutions or industry contacts familiar with the firm’s focus.
What are Nordic Science Capital's investment criteria?
Nordic Science Capital invests in inception-stage biotech ideas emerging from leading Swedish universities. The firm specifically targets scientists who hold patents and collaborates closely in the formation of companies.
How can I apply or pitch to Nordic Science Capital?
Founders can pitch their ideas through the firm's website at ns.capital. It is advisable to include detailed information about the scientific innovation, patent status, and potential market applications in the pitch.
What makes Nordic Science Capital different from other VCs?
The firm differentiates itself through its active co-founder model, where it not only provides capital but also collaborates directly with scientist-founders in company formation and patent filings.
What is the geographic scope of Nordic Science Capital's investments?
Nordic Science Capital primarily focuses on investments in Europe, with a strong emphasis on Sweden and its leading universities.
What is the typical check size for investments?
Specific check sizes are not disclosed, but the firm focuses on pre-seed and seed stage investments, which typically involve smaller amounts compared to later-stage funding.
What kind of post-investment involvement does Nordic Science Capital have?
The firm is actively involved in the companies it invests in, often taking on executive roles and assisting with patent filings and company formation.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.